Amylyx PharmaceuticalsAMLX
AMLX
About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Employees: 123
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 16
61% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 31
39% more capital invested
Capital invested by funds: $188M [Q4 2024] → $262M (+$73.3M) [Q1 2025]
12% more funds holding
Funds holding: 120 [Q4 2024] → 134 (+14) [Q1 2025]
10.74% more ownership
Funds ownership: 72.64% [Q4 2024] → 83.38% (+10.74%) [Q1 2025]
14% less call options, than puts
Call options by funds: $524K | Put options by funds: $606K
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
4%
upside
Avg. target
$12.17
58%
upside
High target
$17
121%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Goldman Sachs Corinne Johnson | 30%upside $10 | Buy Reinstated | 10 Jul 2025 |
Guggenheim Seamus Fernandez | 121%upside $17 | Buy Initiated | 24 Jun 2025 |
Citigroup Geoff Meacham | 56%upside $12 | Buy Initiated | 17 Jun 2025 |
Mizuho Graig Suvannavejh | 4%upside $8 | Outperform Maintained | 14 May 2025 |
HC Wainwright & Co. Andrew Fein | 108%upside $16 | Buy Maintained | 9 May 2025 |
Financial journalist opinion
Based on 7 articles about AMLX published over the past 30 days
Neutral
Business Wire
3 days ago
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025.
Neutral
GlobeNewsWire
4 days ago
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of long-term stockholders following a class action complaint that was filed against Amylyx on July 1, 2025 with a Class Period from November 11, 2022 to November 8, 2023. Our investigation concerns whether the board of directors of Amylyx have breached their fiduciary duties to the company.
Positive
The Motley Fool
2 weeks ago
Why Shares in Amylyx Pharmaceuticals Soared This Week
Shares in Amylyx Pharmaceuticals (AMLX 3.83%) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy recommendation, accompanied by a price target of $17.
Positive
Benzinga
2 weeks ago
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia's (PBH) blockbuster potential.
Neutral
Accesswire
3 weeks ago
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Neutral
Accesswire
4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Neutral
GlobeNewsWire
1 month ago
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Charts implemented using Lightweight Charts™